Standard
Lung and thymic carcinoids : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. / Baudin, E.; ESMO Guidelines Committee.
In:
Annals of Oncology, Vol. 32, No. 4, 2021, p. 439-451.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Baudin, E & ESMO Guidelines Committee 2021, '
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆',
Annals of Oncology, vol. 32, no. 4, pp. 439-451.
https://doi.org/10.1016/j.annonc.2021.01.003APA
Baudin, E., & ESMO Guidelines Committee (2021).
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
Annals of Oncology,
32(4), 439-451.
https://doi.org/10.1016/j.annonc.2021.01.003Vancouver
Baudin E, ESMO Guidelines Committee.
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
Annals of Oncology. 2021;32(4):439-451.
https://doi.org/10.1016/j.annonc.2021.01.003Author
Baudin, E. ; ESMO Guidelines Committee. / Lung and thymic carcinoids : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. In: Annals of Oncology. 2021 ; Vol. 32, No. 4. pp. 439-451.
Bibtex
@article{674940ce58fd4d13aa0d4350bb14e23e,
title = "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆",
keywords = "characterisation, diagnosis, lung carcinoids, prognosis, therapy, thymic carcinoids",
author = "E. Baudin and M. Caplin and R. Garcia-Carbonero and N. Fazio and P. Ferolla and Filosso, {P. L.} and A. Frilling and {de Herder}, {W. W.} and D. H{\"o}rsch and U. Knigge and Korse, {C. M.} and E. Lim and C. Lombard-Bohas and M. Pavel and Scoazec, {J. Y.} and A. Sundin and A. Berruti and {ESMO Guidelines Committee}",
note = "Funding Information: No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. EB has received honoraria from Novartis, Ipsen and Pfizer, research grants from Novartis and he is a member of Ipsen and Novartis speaker's bureau; MC has received research funding and speaker/advisory board honoraria from Ipsen, Novartis, Lexicon and AAA-Pharma; RGC has reported being an advisory board member for Novartis, Ipsen, AAA-Pharma and Pfizer and has received research grants from Pfizer; NF has received honoraria from Novartis, Ipsen, Pfizer, AAA-Pharma, Merck Sharp & Dohme and Merck Serono and research grants from Novartis and Merck Serono; PF has reported advisory board for Novartis, Ipsen, Merck Serono, Pfizer, Lexicon and Italfarmaco and has participated at steering committee for Novartis, Ipsen and Merck Serono; AF is a member of speaker's bureau and has received honoraria from Ipsen, Novartis and Sirtex and has received research grants from Novartis; WWdH has received research grants from Ipsen; DH has received honoraria from Novartis, Ipsen, Pfizer and ROTOP Pharmaka GmbH and research grants from Ipsen and he is a member of Ipsen and Novartis speaker's bureau; UK has received research funding and speaker advisory board honoraria from Ipsen and Novartis; CLB has reported being an advisory board member for Novartis, Pfizer, Ipsen and AAA-Pharma; MP has reported being an advisory board member for and received honoraria from Novartis, Ipsen, Pfizer and Lexicon and has received research grants from Ipsen and Novartis; AB is a member of Novartis speaker's bureau; all other authors have declared no conflicts of interest.",
year = "2021",
doi = "10.1016/j.annonc.2021.01.003",
language = "English",
volume = "32",
pages = "439--451",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",
}
RIS
TY - JOUR
T1 - Lung and thymic carcinoids
T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
AU - Baudin, E.
AU - Caplin, M.
AU - Garcia-Carbonero, R.
AU - Fazio, N.
AU - Ferolla, P.
AU - Filosso, P. L.
AU - Frilling, A.
AU - de Herder, W. W.
AU - Hörsch, D.
AU - Knigge, U.
AU - Korse, C. M.
AU - Lim, E.
AU - Lombard-Bohas, C.
AU - Pavel, M.
AU - Scoazec, J. Y.
AU - Sundin, A.
AU - Berruti, A.
AU - ESMO Guidelines Committee
N1 - Funding Information:
No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. EB has received honoraria from Novartis, Ipsen and Pfizer, research grants from Novartis and he is a member of Ipsen and Novartis speaker's bureau; MC has received research funding and speaker/advisory board honoraria from Ipsen, Novartis, Lexicon and AAA-Pharma; RGC has reported being an advisory board member for Novartis, Ipsen, AAA-Pharma and Pfizer and has received research grants from Pfizer; NF has received honoraria from Novartis, Ipsen, Pfizer, AAA-Pharma, Merck Sharp & Dohme and Merck Serono and research grants from Novartis and Merck Serono; PF has reported advisory board for Novartis, Ipsen, Merck Serono, Pfizer, Lexicon and Italfarmaco and has participated at steering committee for Novartis, Ipsen and Merck Serono; AF is a member of speaker's bureau and has received honoraria from Ipsen, Novartis and Sirtex and has received research grants from Novartis; WWdH has received research grants from Ipsen; DH has received honoraria from Novartis, Ipsen, Pfizer and ROTOP Pharmaka GmbH and research grants from Ipsen and he is a member of Ipsen and Novartis speaker's bureau; UK has received research funding and speaker advisory board honoraria from Ipsen and Novartis; CLB has reported being an advisory board member for Novartis, Pfizer, Ipsen and AAA-Pharma; MP has reported being an advisory board member for and received honoraria from Novartis, Ipsen, Pfizer and Lexicon and has received research grants from Ipsen and Novartis; AB is a member of Novartis speaker's bureau; all other authors have declared no conflicts of interest.
PY - 2021
Y1 - 2021
KW - characterisation
KW - diagnosis
KW - lung carcinoids
KW - prognosis
KW - therapy
KW - thymic carcinoids
U2 - 10.1016/j.annonc.2021.01.003
DO - 10.1016/j.annonc.2021.01.003
M3 - Journal article
C2 - 33482246
AN - SCOPUS:85101051556
VL - 32
SP - 439
EP - 451
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 4
ER -
